ADDRESSING PERVASIVE TREATMENT CHALLENGES IN DERMATOLOGY
Veradermics has cultivated a dermatology-focused pipeline of five novel product candidates for large-market conditions seen in adults and children that are overdue for new treatment approaches including common warts (verruca vulgaris), molluscum contagiosum, alopecia areata, androgenetic alopecia (pattern hair loss), and atopic dermatitis.
We have a rapidly advancing diverse pipeline of first-in-class candidates
Program Indication
MOA Delivery
PRE-IND
PHASE 1
PHASE 2
PHASE 3
VDMN
Common Warts
Candida Antigen Extract
Immunotherapy
Dissolvable Microarray
VDMC
Molluscum Contagiosum
Topical
New Chemical Entity
Antiviral
VDAA
Alopecia Areata
Confidential
Topical against
Clinically Validated Target
VDPHL
Pattern Hair Loss
Confidential
Oral against
Clinically Validated Target
VDAD
Atopic Dermatitis
Oral
New Chemical Entity
Against Clinically Validated Target